Edith Mathiowitz

Perosphere, Inc. operates as a pharmaceutical company that focuses on addressing unmet medical needs associated with anticoagulant therapies. Its drug product candidate, ciraparantag, is an intravenously administered small synthetic water soluble new molecular entity rationally designed for use as a broad-spectrum reversal agent for anticoagulants including heparins and the new oral anticoagulants allowing rapid re-establishment of a normal blood coagulation state when clinically indicated. The firm's device product candidate is point-of-care coagulometer, a hand-held device that tests fresh or citrated whole blood. The system is designed for broad-spectrum monitoring of the activity of anticoagulants and their corresponding antidotes, across drug classes, in a hospital setting at a patient's bedside. The company was founded by Sasha H. Bakhru, Edith Mathiowitz, Bryan E. Laulicht and Solomon S. Steiner in 2011 and is headquartered in Danbury, CT.

Spherics, Inc. develops pharmaceutical products to address the clinical needs of neurological disorders. Its technology is based on proprietary bio adhesive, biodegradable polymers, enhancers, and coatings. The company has established two distinct drug delivery systems: nano and macro spheres. Spherics was founded by Dr. Edith Mathiowitz in 1997 and is located in Mansfield, MA.

Sentient Bioscience, Inc. develops technology for embolization therapy and site-specific drug delivery to treat cancer and other diseases. The company was founded by Jean Francois H. Geschwind, Edith Mathiowitz and Timothy Murphy on August 14, 2008 and is headquartered in Providence, RI.